Anthropic Launches Claude Science to Challenge DeepMind's Dominance in AI-Driven Research
Anthropic debuts Claude Science, a standalone product for computational biology and drug discovery, positioning itself as a serious contender in scientific AI.
Last verified:
BLUF
According to MIT Technology Review, Anthropic unveiled Claude Science on June 30, 2026, positioning it as the company’s flagship product for autonomous research support in computational biology and drug development. The launch—paired with the recent recruitment of Nobel laureate John Jumper from Google DeepMind—marks a direct challenge to DeepMind’s decade-long dominance in AI for scientific applications.
Claude Science’s Capabilities and Positioning
Anthropic announced Claude Science at a private event for pharmaceutical executives, biotech founders, and researchers. The product operates similarly to Claude Code, accepting high-level instructions and autonomously executing meaningful research tasks through specialized tools optimized for computational biology and drug discovery workflows. According to MIT Technology Review, Claude Science is now accessible to all paid Claude subscribers, representing a departure from Anthropic’s earlier October 2025 release of life sciences plugins, which were narrower in scope.
The elevation of Claude Science to the same product tier as Claude Code and Claude Cowork reflects Anthropic’s strategic bet on scientific AI. Eric Kauderer-Abrams, Anthropic’s head of life sciences, told MIT Technology Review that the launch demonstrates the company’s commitment to its mission: “Our mission is to develop AI that serves humanity’s long-term well-being, and we believe that by far the greatest opportunity to do that is in the life sciences.”
Anthropic’s Challenge to DeepMind’s Scientific Hegemony
For the past decade, Google DeepMind has set the standard in AI for science. CEO Demis Hassabis and researcher John Jumper received the Nobel Prize in Chemistry for their work on AlphaFold, and DeepMind has contributed to advances in meteorology and materials science. However, the emergence of large language model agents—particularly Anthropic’s Opus series—capable of autonomous work since late 2025 has shifted the competitive landscape. According to MIT Technology Review, DeepMind is now “playing catch-up” in coding applications, the most lucrative LLM use case.
Anthropic’s structural advantages strengthen its position. Unlike OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei holds a PhD and brings deep scientific credibility. Many researchers already use Claude Code for tasks involving computational components, a natural bridge to Claude Science adoption.
The Jumper Factor
The hire of John Jumper, who departed Google DeepMind after co-winning the Nobel Prize, signals both Anthropic’s attractiveness to elite scientific talent and DeepMind’s vulnerability in the generalist LLM era. According to MIT Technology Review, Jumper’s move occurred earlier in June 2026. His recruitment underscores that DeepMind’s specialized scientific infrastructure—once its moat—faces disruption from LLM agents that can apply reasoning across domains.
Why This Matters
Claude Science represents a structural shift in how scientific research may be conducted. If the product delivers on autonomous research execution in drug development and computational biology, teams currently managing manual literature review, data curation, and computational workflows will face pressure to adopt or lose productivity advantage. Pharma and biotech executives weighing vendor partnerships in AI-driven discovery now have a credible alternative to DeepMind’s specialized tools. The broader implication: the LLM era may consolidate scientific AI around general-purpose agents rather than domain-specific models, favoring companies like Anthropic that command broad researcher trust.
Frequently Asked Questions
What is Claude Science and how does it differ from Claude Code?
Claude Science is a standalone product that autonomously performs research tasks in computational biology and drug development. Like Claude Code for software engineering, it accepts high-level instructions and has specialized tools. Unlike Anthropic's October 2025 life sciences plugins, Claude Science is a full-featured product ranked equally with Claude Code and Claude Cowork.
Who can access Claude Science?
Claude Science is available to all paid Claude subscribers, according to MIT Technology Review. Anthropic is also using it internally for research into drugs for rare, neglected diseases.
Why does John Jumper's move to Anthropic matter?
Jumper, a Nobel Prize winner for his work on AlphaFold at Google DeepMind, recently joined Anthropic. His departure signals both DeepMind's vulnerability in the LLM era and Anthropic's credibility in scientific AI.